Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)

Idenix Pharmaceuticals, Inc.

, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it will present data on IDX719, the Company's pan-genotypic HCV NS5A inhibitor, at the 48^th Annual Meeting of the European Association for the Study of the Liver (EASL) which is being held April 24 – 28, 2013 in Amsterdam, the Netherlands. Full abstracts can now be viewed at the EASL website at www.easl.eu.